Xanthohumol and Metabolic Syndrome


The purpose of this study is to determine the pharmacokinetics (PK) of xanthohumol (XN). Small amounts of xanthohumol occur naturally in hops, used to make beer, and XN is also found in beer itself. Studies in animals have shown that XN can lower blood sugar and blood lipids such as triglycerides, which can contribute to heart disease. The purpose of this study is to see how much of the XN is absorbed into the blood and how fast it leaves the body when taken by mouth. Once the PK study has been done, the investigators' long-term goal is to learn if xanthohumol can lower risk factors for heart disease and type-2 diabetes in humans.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 2012


  • Dietary Supplement: Xanthohumol
    • PK study with one capsule of one of the three doses randomly assigned

Arms, Groups and Cohorts

  • 20 mg
    • Single dose 20 mg Xanthohumol
  • 60 mg
    • Single dose 60 mg Xanthohumol
  • 180 mg
    • Single dose 180 mg Xanthohumol

Clinical Trial Outcome Measures

Primary Measures

  • Levels of xanthohumol and metabolites.
    • Time Frame: 6 days
    • The outcome measures will be the levels of xanthohumol and its metabolites in blood and urine following a single dose of 20 mg, 60mg, or 180 mg of xanthohumol over a course of six days. These levels will be used to determine the pharmacokinetics of xanthohumol in humans.

Participating in This Clinical Trial

  • BMI 18-32 kg/m2 (to avoid confounders with extreme obesity). – Smoking or non-smoking. – Having normal or clinically acceptable physical examination and clinical laboratory tests. – Willing to abstain from beer consumption for four days prior to and during the study because beer contains XN and related prenylated (PN) flavonoids, such as IX, 8-PN and 6-PN. – Not currently taking prescription drugs. – Not having had acute medical conditions, such as hospitalizations or surgeries, at least three months prior to entry into the study. – If female, not pregnant (as confirmed by urine pregnancy test), breastfeeding, or planning to become pregnant before completing the study, and using effective method of contraception (hormonal methods NOT permitted). – If male with a partner of childbearing potential, willing to inform their partner of their participation in this clinical study and use highly effective methods of birth control during the study. – Not currently following an extreme diet, such as Atkin's, Zone or Ornish, and willing to maintain their current diet without extreme changes for the duration of the study.
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: 60 Years

    Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

    Investigator Details

    • Lead Sponsor
      • Oregon State University
    • Collaborator
      • Oregon Health and Science University
    • Provider of Information About this Clinical Study
      • Principal Investigator: Jan Frederik Stevens, Associate Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences, College of Pharmacy – Oregon State University
    • Overall Official(s)
      • Jan F Stevens, PhD, Principal Investigator, Oregon State University
      • Jon Q Purnell, MD, Principal Investigator, Oregon Health and Science University

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.